The Technical Analyst
Eiger BioPharmaceuticals [EIGR]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Eiger BioPharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $1.725
America/New_York / 10 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2.55 mill |
| EPS: | -58.50 |
| P/E: | -0.0300 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 1.479 mill |
| Avg Daily Volume: | 0.117 mill |
| RATING 2024-04-10 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0300 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.0300 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.383 - 3.40 ( +/- 42.13%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-11-02 | Kayne Richard A | Buy | 23 398 | Common Stock |
| 2023-11-01 | Kayne Richard A | Buy | 100 000 | Common Stock |
| 2023-10-31 | Kayne Richard A | Buy | 130 509 | Common Stock |
| 2023-10-31 | Kayne Richard A | Buy | 12 345 | Common Stock |
| 2023-10-31 | Kayne Richard A | Buy | 11 987 | Common Stock |
| INSIDER POWER |
|---|
| 57.31 |
| Last 89 transactions |
| Buy: 3 414 696 | Sell: 449 818 |
Forecast:
16:00 - $1.721
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.721
Forecast 2: 16:00 - $1.721
Forecast 3: 16:00 - $1.721
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.725 (0.00% ) |
| Volume | 0.130 mill |
| Avg. Vol. | 0.117 mill |
| % of Avg. Vol | 110.44 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EIGR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
EIGR
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
Latest Press Releases
2024-04-01 11:12:00 - Press Release
Eiger Biopharmaceuticals Files For Voluntary Chapter 11 Protection
Announces “stalking horse” agreement for the sale of zokinvy ® (lonafarnib) patient access to zokinvy ® to continue uninterrupted palo alto, calif., april 01, 2024 (globe newswire) -- eiger biopharmaceuticals, inc. (nasdaq:eigr) today announced that it and its direct subsidiaries have filed voluntary petitions for chapter 11 protection under the united states bankruptcy code in the united states bankruptcy court for the northern district of texas.
2024-01-18 17:49:00 - Press Release
Eiger And Partner, Anges, Receive Approval For Zokinvy® (lonafarnib) For Hutchinson- Gilford Progeria Syndrome And Processing-deficient Progeroid Laminopathies In Japan
Clinical trial data demonstrated zokinvy treatment extended life by an average of 4.3 years in children and young adults with hutchinson-gilford progeria eiger to receive $500,000 approval milestone payment from anges zokinvy approved in the u.s. (2020), 30 european countries (2022), and now japan (2024) palo alto, calif. , jan. 18, 2024 /prnewswire/ -- eiger biopharmaceuticals, inc. (nasdaq:eigr), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it and its partner anges, inc. received marketing approval from the ministry of health, labour and welfare for zokinvy (lonafarnib), a treatment for hutchinson-gilford progeria syndrome (hgps) and processing deficient progeroid laminopathy (pdpl).
2024-01-04 08:00:00 - Press Release
Eiger Biopharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split
Palo alto, calif. , jan. 4, 2024 /prnewswire/ -- eiger biopharmaceuticals, inc. (nasdaq:eigr) (the "company"), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 (the "reverse stock split").
2023-09-12 16:05:00 - Press Release
Eiger To Discontinue Phase 3 Limt-2 Trial Of Peginterferon Lambda In Patients With Chronic Hepatitis Delta
Palo alto, calif., sept. 12, 2023 /prnewswire/ -- eiger biopharmaceuticals, inc. (nasdaq:eigr), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced its decision to discontinue the phase 3 limt-2 study of peginterferon lambda in patients with chronic hepatitis delta (chd).
2023-09-05 16:05:00 - Press Release
Eiger Biopharmaceuticals To Present At H.c. Wainwright 25th Annual Global Investment Conference
Palo alto, calif. , sept. 5, 2023 /prnewswire/ -- eiger biopharmaceuticals, inc. (nasdaq:eigr), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that david apelian, md, phd, mba, ceo of eiger, will present a company overview at the h.c.
Latest News
2024-04-01 20:59:00 - Market Watch
Healthcare stocks fade as obesity-drug optimism fades
Healthcare companies fell sharply Monday as ebullience about a new class of weight control drugs subsided.
2023-09-13 09:20:44 - InvestorPlace
Why Is Eiger BioPharmaceuticals (EIGR) Stock Down 31% Today?
Eiger BioPharmaceuticals (NASDAQ: EIGR ) stock is falling on Wednesday after the biopharmaceutical company halted a Phase 3 clinical trial. According to a press release from the company, it has discontinued its Phase 3 LIMT-2 study.
2023-06-16 20:24:53 - Seeking Alpha
Eiger BioPharmaceuticals: Wall Street Has High Expectations For Faltering Battleground Stock
Wall Street Analysts have high expectations for Eiger. Eiger has a modest pipeline. Expect near term data to impact the stock in a big way.
2023-02-09 22:35:23 - Pulse2
EIGR Stock: 23.53% Surge Explanation
The stock price of Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR) surged by 23.53% today. This is why.
2023-01-18 13:58:00 - Barrons
7 Cheap But Risky Biotech Stocks
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.
2022-12-29 14:07:13 - PennyStocks
Best Penny Stocks To Buy? 4 To Watch Before 2023
2022-12-28 13:16:55 - PennyStocks
Best Penny Stocks To Buy Now? 4 Stocks Under $4 To Watch
2022-12-07 16:05:00 - PRNewsWire
Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022
Live Conference Call and Webcast at 8:30 AM ET PALO ALTO, Calif. , Dec. 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, December 8, 2022, at 8:30 AM Eastern Time, to discuss the results of the Phase 3 D-LIVR study of lonafarnib-based treatments for HDV.
2022-11-26 02:58:02 - Seeking Alpha
Eiger BioPharmaceuticals: A Compelling High Beta Story
Today, we revisit the investment case around Eiger BioPharmaceuticals for the first time in more than a year and a half. Eiger has one product on the market and is rapidly advancing a powerful 'sum of the parts' story.
2022-11-03 21:25:29 - Seeking Alpha
Eiger BioPharmaceuticals, Inc. (EIGR) Q3 2022 Earnings Call Transcript
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR ) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Sarah Mathieson - Senior Vice President, Corporate Affairs David Cory - President and CEO Sri Ryali - Chief Financial Officer Eldon Mayer - Chief Commercial Officer Ingrid Choong - Senior Vice President, Clinical Development Colin Hislop - Senior Vice President, Clinical & Development Operations Colleen Craig - Vice President, Metabolic Diseases Conference Call Participants Maury Raycroft - Jefferies Charlie Moore - Baird Bert Hazlett - BTIG Farhana Sakloth - Ladenburg Operator Welcome to the Eiger BioPharmaceuticals Third Quarter 2022 Financial Results and Business Update Conference Call...